Aegerion Pharmaceuticals
AEGR
AEGR was delisted on the 29th of November, 2016.
101 hedge funds and large institutions have $114M invested in Aegerion Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 43 increasing their positions, 30 reducing their positions, and 19 closing their positions.
43% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 30
7% less funds holding
Funds holding: 109 → 101 (-8)
19% less call options, than puts
Call options by funds: $539K | Put options by funds: $669K
42% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 19
66% less capital invested
Capital invested by funds: $334M → $114M (-$220M)
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$4.03M |
| 2 |
BC
Broadfin Capital
New York
|
+$3.1M |
| 3 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
+$1.84M |
| 4 |
AC
Armistice Capital
New York
|
+$1.83M |
| 5 |
Goldman Sachs
New York
|
+$1.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.35M |
| 2 |
Millennium Management
New York
|
-$5.97M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$3.7M |
| 4 |
Morgan Stanley
New York
|
-$3.48M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
-$2.64M |
AEGR Hedge Fund Activity: Q1 2016 in Review
101 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Aegerion Pharmaceuticals (AEGR) for Q1 2016, worth a combined $114M — down 66% from $334M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of AEGR and 11 opened new positions — a net loss of 8 holders — while 30 trimmed existing stakes and 43 added.
The largest buyer was Renaissance Technologies, adding an estimated $4.03M. The largest seller was Fidelity Investments, cutting an estimated $7.35M.
- 101 institutional investors held Aegerion Pharmaceuticals (AEGR) as of Q1 2016, down from 109 in Q4 2015.
- Funds reported $114M of Aegerion Pharmaceuticals stock for Q1 2016, down 66% quarter-over-quarter.
- 11 funds opened new Aegerion Pharmaceuticals positions in Q1 2016 and 19 closed out, a net change of -8 holders.
- The largest Aegerion Pharmaceuticals buyer in Q1 2016 was Renaissance Technologies, an estimated $4.03M added.
- The largest Aegerion Pharmaceuticals seller in Q1 2016 was Fidelity Investments, an estimated $7.35M sold.
Based on aggregated 13F filings for Q1 2016.